EPO Patent Bulletin - CAR for HVG Disease Treatment

ChangeBridge: EPO Bulletin - Peptides (C07K)

Published March 18th, 2026

Detected March 23rd, 2026

Summary

The European Patent Office has published a patent bulletin regarding a CAR for use in treating HVG disease. The patent, filed by Medizinische Hochschule Hannover and Technische Universität Braunschweig, describes a nucleic acid encoding a chimeric antigen receptor with specificity for HLA-A*02 for use in suppressing immune rejection of transplants.

View original document View source feed page

What changed

This document is a patent bulletin from the European Patent Office (EPO) detailing a new patent application (EP4671278A3) for a Chimeric Antigen Receptor (CAR) designed for treating HVG disease. The patent, filed by Medizinische Hochschule Hannover and Technische Universität Braunschweig, focuses on a nucleic acid encoding a CAR with HLA-A02 specificity, intended to suppress the host's immune response against a transplant in patients negative for HLA-A02. The invention aims to facilitate immune suppression and prevent rejection of transplanted organs or tissues.

This patent publication is primarily informational for entities involved in pharmaceutical research, development, and manufacturing, particularly in the fields of immunotherapy and transplantation. It does not impose immediate compliance obligations on regulated entities but highlights a specific area of innovation in treating HVG disease and transplant rejection. Companies operating in this space should be aware of this patent's existence and scope as it may impact future research and commercialization strategies.

Source document (simplified)

← EPO Patent Bulletin

CAR FOR USE IN THE TREATMENT OF HVG DISEASE

Search Report EP4671278A3 Kind: A3 Mar 18, 2026

Applicants

Medizinische Hochschule Hannover, Technische Universität Braunschweig

Inventors

JÄCKEL, Elmar, MOYAN, Fatih, HUST, Michael

Abstract

The invention provides a nucleic acid encoding an optimized and far potent chimeric antigen receptor having specificity for HLA-A02. Also provided is its use in the treatment of HvG disease in a patient having received a transplant, for use in suppressing the host's immune response directed against the transplant. The encoded fusion protein is adapted for use in suppressing the immune rejection of a transplant which contains or expresses HLA-A02 in a recipient patient who is negative for HLA-A02, i.e. the patient prior to transplantation does not express HLA-A02. The encoded fusion protein is a chimeric antigen receptor (CAR), which upon expression in regulatory T-cells (Treg) causes a specific suppressor activity of the regulatory T-cells in the presence of HLA-A*02.

IPC Classifications

A61P 37/06 20060101AFI20260206BHEP C07K 16/28 20060101ALI20260206BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →